INSULIN GLULISINE + INSULIN GLARGINE
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 1
Conditions
Diabetes Mellitus, Type 1
Trial Timeline
May 1, 2011 → Oct 1, 2012
NCT ID
NCT01202474About INSULIN GLULISINE + INSULIN GLARGINE
INSULIN GLULISINE + INSULIN GLARGINE is a approved stage product being developed by Sanofi for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT01202474. Target conditions include Diabetes Mellitus, Type 1.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01202474 | Approved | Completed |
| NCT00135096 | Phase 3 | Completed |
| NCT00135057 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 1